Asia-Pacific Blood Glucose Monitoring Market Size

Asia-Pacific Blood Glucose Monitoring Market Analysis

The Asia-Pacific Blood Glucose Monitoring Market size is estimated at USD 3.77 billion in 2024, and is expected to reach USD 5.54 billion by 2029, growing at a CAGR of 7.69% during the forecast period (2024-2029).

The growth of the Asia-Pacific Diabetes Care Devices Market was positively influenced by the COVID-19 pandemic. Individuals with diabetes who contracted COVID-19 may experience higher blood glucose levels, abnormal glucose fluctuations, and diabetic complications. The presence of diabetes in individuals with COVID-19 led to a significant increase in the severity and mortality of the virus, particularly in those with type 1 (T1DM) or type 2 diabetes mellitus (T2DM) and poor glycemic control. Additionally, the onset of hyperglycemia and diabetes (both T1DM and T2DM) has been increasingly observed in the context of COVID-19 and has been linked to worse outcomes. 

Regular monitoring of a patient's blood glucose levels is crucial to prevent exacerbation, highlighting the importance of blood glucose monitoring devices. The pandemic emergency has resulted in a surge in remote care from both patients and healthcare providers, along with the removal of various longstanding regulatory barriers.

Asia-Pacific has countries with the highest diabetic populations, such as China and India, with an average prevalence rate of more than 8.5%. Blood glucose monitoring devices are used for effective diabetes diagnosis and treatment. A rise in the diabetic population drives the market by increasing the use of blood glucose monitoring devices. Obesity is also considered one of the major factors contributing to the disease condition, mainly type 2 diabetes. Also, other factors such as technological innovations and advances provide convenience in measuring blood glucose levels. These devices help in the early detection of hypo- and hyperglycemic conditions, which tend to drive the market for glucose monitoring market.

The incidence of newly diagnosed cases of Type 1 and Type 2 diabetes is observed to be on the rise, primarily due to factors such as obesity, unhealthy diet, and lack of physical activity. This increase in diabetes cases, along with the corresponding rise in healthcare expenditure, is indicative of the growing utilization of diabetic care products in developed countries. Additionally, the market growth is being driven by the increasing adoption of insulin delivery devices and the escalating prevalence of diabetes. To capture a significant market share, leading manufacturers are focusing on technological advancements and the development of advanced products. As a result of these factors, the analyzed market is expected to experience growth during the specified period of analysis.